Family

Loading Family data...

• 15 United States
• 10 France
• 8 Japan
• 7 China
• 5 Korea
• 2 Other

Patent Owner(s)

Patent Owner	Address
ENZO THERAPEUTICS INC	FARMINGDALE NY 11735

International Classification(s)

• A61K:PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOS....

• 2017 Application Filing Year
• A61K Class
• 21227 Applications Filed
• 12841 Patents Issued To-Date
• 60.50 % Issued To-Date

Inventor(s)

Inventor Name	Address	# of filed Patents	Total Citations
Ilan, Yaron	Jerusalem, IL	103	375
# of filed Patents : 103 Total Citations : 375
Margalit, Maya	Abu Gosh, IL	17	62
# of filed Patents : 17 Total Citations : 62

Cited Art Landscape

Load Citation

• No Cited Art to Display

Loading Cited Art Landscape...

Patent Citation Ranking

• 0 Citation Count
• A61K Class

• 0 % this patent is cited more than
• 7 Age

Forward Cite Landscape

Load Citation

• No Forward Cites to Display

Loading Forward Cite Landscape...

Maintenance Fees

Fee	Large entity fee	small entity fee	micro entity fee	due date
7.5 Year Payment	$3600.00	$1800.00	$900.00	Sep 6, 2025
11.5 Year Payment	$7400.00	$3700.00	$1850.00	Sep 6, 2029

Fee	Large entity fee	small entity fee	micro entity fee
Surcharge - 7.5 year - Late payment within 6 months	$160.00	$80.00	$40.00
Surcharge - 11.5 year - Late payment within 6 months	$160.00	$80.00	$40.00
Surcharge after expiration - Late payment is unavoidable	$700.00	$350.00	$175.00
Surcharge after expiration - Late payment is unintentional	$1,640.00	$820.00	$410.00

DATE PUBLISHED	PUBLICATION/PATENT NO.	PUBLICATION TYPE
March 06, 2018	US,9907810,B1   US9907810B1	GRANTED PATENT AS FIRST PUBLICATION
February 15, 2018	US,20180042951,A1   US20180042951A1	FIRST PUBLISHED PATENT APPLICATION

Full Text

US Patent No: 9907810

Glucocerebroside treatment of liver disorders

---

Abstract

---

The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects. This method comprises the administration of a naturally occurring, mammalian intermediary metabolite or T cell receptor ligand, preferably a glucosylceramide, to a mammalian subject. In a preferred embodiment, such mammalian subjects are human beings.

---

 

---

Description

---

Claims

---

Claims data not available

---

Legal Events

 

• MAFP2021
• I2018
• P2018
• STCF2018
• F2017
• PD2003

Date	Code	Event	Description
Apr 13, 2021	MAFP	MAINTENANCE FEE PAYMENT	free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY year of fee payment: 4
Mar 06, 2018	I	Issuance
Feb 15, 2018	P	Published
Feb 14, 2018	STCF	INFORMATION ON STATUS: PATENT GRANT	free format text: PATENTED CASE
Jul 12, 2017	F	Filing
Feb 27, 2003	PD	Priority Date